Skip to main content
. 2015 Oct 26;6(42):44274–44288. doi: 10.18632/oncotarget.6236

Figure 5. 244-MPT inhibits tumor growth in a gefitinib-resistant NSCLC xenograft mouse model.

Figure 5

(A) Treatment with 244-MPT significantly suppresses NSCLC xenograft tumor volume compared with the vehicle-treated group. The asterisks (*, **) indicate a significant (p < 0.05, p < 0.01, respectively) decrease in tumor volume compared to the vehicle-treated control. (B) Representative photographs show external appearance of tumors. (C) 244-MPT has no effect on the body weight of mice. (D) Immunohistochemistry analysis was used to determine the level of Ki-67, and phosphorylation of EGFR, Akt and ERK1/2 in tumors treated with 244-MPT compared tumors treated with vehicle only. Representative photographs for each antibody and each group are shown. The integrated optical density (IOD) was evaluated using the Image-Pro Premier software offline (v.9.0) program. The asterisks (*, **) indicate a significant (p < 0.05, p < 0.01, respectively) decrease in compound-treated samples compared to vehicle-treated samples.